Mazyar Shadman, M.D., M.P.H. from Fred Hutchinson Cancer Research Center discusses A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
For more information, click the link below -
This is a dose-escalation phase I/II analysis of CD20-specific therapy with CAR T cells.
Patients undergo leukapheresis and, if necessary for disease control, can receive treatment afterward. Patients first undergo intravenous cyclophosphamide (IV). Fludarabine IV can also be given to patients. After 36-96 hours, patients undergo 20-30 minutes of CD20-specific CAR T cell infusion IV.
For about 15 months, patients will be actively involved in the research. The total duration includes the time for the T cells to be generated, the infusion of the T cells, and about 12 months after the infusion of the T cells. Patients are treated for a period of 15 years following the completion of study therapy.